IDEAYA Biosciences Q3 2023 Earnings Report

IDEAYA Biosciences EPS Results

• Actual EPS: -$0.46
• Consensus EPS: -$0.49
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

IDEAYA Biosciences Revenue Results

• Actual Revenue: $8.00 million
• Expected Revenue: $8.14 million
• Beat/Miss: Missed by -$140.00 thousand
• YoY Revenue Growth: +128.60%

IDEAYA Biosciences Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: Before Market Opens
• Conference Call Date: Tuesday, November 7, 2023
• Conference Call Time: 7:00AM ET

IDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for oncology patients. Headquartered in South San Francisco with additional research facilities in Santa Monica, California, Ideaya applies a synthetic lethality approach to identify tumor-specific vulnerabilities. The company’s research platform integrates functional genomics, cell biology and bioinformatics to uncover novel targets and predictive biomarkers that guide development of small-molecule therapies.

Ideaya’s pipeline includes multiple programs directed at key nodes within the DNA damage response and other synthetic lethal pathways. Leading candidates in clinical evaluation include small-molecule inhibitors targeting POLθ (DNA polymerase theta) and ATR (ataxia telangiectasia and Rad3-related), designed to exploit defects in tumor DNA repair mechanisms. In addition to its internal portfolio, Ideaya has established collaborations with major pharmaceutical partners, including GSK and Genentech, to accelerate discovery and co-development of new oncology assets.

Since its founding in 2017 as a precision oncology spinout, Ideaya has grown through strategic research alliances and an initial public offering in 2020. The company’s scientific teams work in concert with academic institutions and contract research organizations across North America and Europe, advancing both monotherapy and combination approaches in a variety of solid and hematologic malignancies. Ideaya’s global footprint supports early-stage discovery through late-stage clinical trials.

Ideaya is led by its co-founder and President and Chief Executive Officer, Anna Protopapas, Ph.D., who brings extensive experience in oncology drug development. Supported by a leadership team with prior roles at leading biotech and pharmaceutical firms, the company’s board and management are committed to translating cutting-edge genomic insights into personalized cancer treatments.